Vera Therapeutics Reports Positive Results from ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy, Meeting Primary Endpoint

Vera Therapeutics (VERA) announced positive topline results from its ORIGIN Phase 3 trial of atacicept for IgA nephropathy (IgAN), with the drug achieving a statistically significant 42% reduction in proteinuria compared to placebo at week 36 (p<0.0001). The safety profile was comparable to placebo, and the company plans to engage with the FDA regarding a Biologics License Application submission in Q4 2025, potentially leading to a commercial launch in 2026; however, eGFR results from the ongoing ORIGIN 3 trial have not been disclosed.

Analysis

Vera Therapeutics (VERA) has reported significantly positive topline results from its ORIGIN Phase 3 trial for atacicept in IgA nephropathy (IgAN), with the drug achieving its primary endpoint of a 46% reduction in proteinuria from baseline and a statistically significant 42% reduction compared to placebo at week 36 (p<0.0001). This efficacy, coupled with a favorable safety profile comparable to placebo, positions atacicept as a potentially leading therapy, with results reinforcing or improving upon the Phase 2b trial. The company plans to engage with the FDA and submit a Biologics License Application (BLA) in Q4 2025, aiming for a potential U.S. commercial launch in 2026. However, investors should note the non-disclosure of eGFR results from the ongoing ORIGIN 3 placebo-controlled trial, which continues until 2027 for two-year data, and that the BLA submission timeline has been extended to Q4 2025. Insider activity reveals the President and CEO, Marshall Fordyce, executed 15 sales transactions totaling 72,188 shares for approximately $2,852,651 in the past six months, with no insider purchases. Institutional ownership changes in Q1 2025 show mixed sentiment: Paradigm Biocapital Advisors and Logos Global Management fully exited their positions, removing 1,437,339 and 875,000 shares respectively, while Lord, Abbett & Co. LLC significantly reduced its holding by 1,005,140 shares (-87.1%). Conversely, Vestal Point Capital added 1,425,000 shares (+132.6%), Deerfield Management added 1,050,000 shares, and Kynam Capital Management increased its stake by 942,090 shares (+64.6%). Analyst coverage includes an "Outperform" rating from Wolfe Research as of February 2025, with no sell ratings reported.

Key Decisions for Investors

• The strong Phase 3 proteinuria data significantly de-risks atacicept's clinical profile for IgAN, warranting close attention to upcoming FDA interactions and the planned BLA submission in Q4 2025.
• Investors should monitor for the eventual release of eGFR data from the ORIGIN 3 trial, expected in 2027, which will be crucial for a complete assessment of atacicept's long-term kidney function benefits.
• Caution is advised given the CEO's recent share sales, the pushed BLA timeline, and the mixed institutional investor activity, suggesting a balanced approach while awaiting further clinical and regulatory milestones.